380 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by ProVise Management Group LLC

ProVise Management Group LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 380 shares of the company’s stock, valued at approximately $211,000.

A number of other hedge funds have also bought and sold shares of the company. Orion Portfolio Solutions LLC grew its holdings in IDEXX Laboratories by 8.3% during the 4th quarter. Orion Portfolio Solutions LLC now owns 2,910 shares of the company’s stock valued at $1,583,000 after purchasing an additional 222 shares during the last quarter. Team Hewins LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $379,000. US Bancorp DE raised its holdings in shares of IDEXX Laboratories by 2.6% in the fourth quarter. US Bancorp DE now owns 19,820 shares of the company’s stock worth $11,001,000 after buying an additional 502 shares during the period. Moreno Evelyn V bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $233,000. Finally, Financial Advisors Network Inc. purchased a new position in IDEXX Laboratories during the 4th quarter valued at $240,000. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the sale, the director now directly owns 161 shares in the company, valued at approximately $87,068.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 0.1 %

IDXX stock traded up $0.40 during trading on Friday, hitting $516.50. 267,200 shares of the company’s stock traded hands, compared to its average volume of 546,767. The firm has a market capitalization of $42.66 billion, a P/E ratio of 50.00, a PEG ratio of 4.21 and a beta of 1.27. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The business has a fifty day simple moving average of $509.96 and a two-hundred day simple moving average of $523.39.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last announced its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.13. The business had revenue of $964.10 million for the quarter, compared to analysts’ expectations of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IDXX. Barclays reduced their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a report on Tuesday, January 30th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. raised their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $580.38.

Check Out Our Latest Stock Report on IDEXX Laboratories

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.